CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Andrea Tortelli

OPENALEX: A5075949374↗ORCID: 0000-0003-0437-3018↗

Affiliations

Organizations

Amsterdam University Medical Centersauthorship · NL Centro de Investigación Biomédica en Red de Salud Mentalauthorship · ES Etablissements de Santé Mentaleauthorship · FR Hospital General Universitario Gregorio Marañónauthorship · ES Icahn School of Medicine at Mount Sinaiauthorship · US Insermauthorship · FR Institut Mondor de Recherche Biomédicaleauthorship · FR Université Paris-Est Créteilauthorship · FR University of Amsterdamauthorship · NL University of Bolognaauthorship · IT

Public evidence

11 connected articles

Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMC The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC Cannabis use and cognitive biases in people with first-episode psychosis and their siblings.2024 · Europe PMC The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMC Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open Access The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open Access Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

2021 · PubMed Central Open Access

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access

Andrea Tortelli - Medical Cannabis Research Engine